论文部分内容阅读
目的探讨泌乳素诱导蛋白(PIP)mRNA对估计乳腺癌预后的临床价值。方法用逆转录-聚合酶链式反应(RT-PCR)法,检测121例乳腺癌患者外周血中PIP mRNA表达情况,另抽取30例乳腺良性疾病患者外周血标本作为对照组。结果 121例乳腺癌患者外周血中PIP mRNA有38例表达,阳性率为31.4%,对照组中PIP mRNA表达为阴性。两组比较差异有显著性(P<0.05)。PIPmRNA阳性表达与患者的淋巴结转移状况、原发肿瘤大小、分期、病理分级显著相关(P<0.05);而与患者的年龄、病理类型、ER、PR等无显著相关(P>0.05)。结论外周血PIP mRNA阳性表达与乳腺癌不良预后有关。
Objective To investigate the clinical value of prolactin-inducible protein (PIP) mRNA in estimating the prognosis of breast cancer. Methods The expression of PIP mRNA in peripheral blood of 121 patients with breast cancer was detected by reverse transcription polymerase chain reaction (RT-PCR). Thirty patients with benign breast disease were selected as the control group. Results There were 38 cases of PIP mRNA in peripheral blood of 121 patients with breast cancer, the positive rate was 31.4%. The expression of PIP mRNA in the control group was negative. There was significant difference between the two groups (P <0.05). PIP mRNA expression was significantly correlated with lymph node metastasis, primary tumor size, stage and pathological grade (P <0.05), but not with age, pathological type, ER, PR (P> 0.05). Conclusion The positive expression of PIP mRNA in peripheral blood is related to the poor prognosis of breast cancer.